In Q1 2026, Eventide Asset Management held 213 positions worth $4.9B. They initiated 30 new positions and exited 138. Their largest holding was GH ($218.1M). Portfolio value shrank -6.7% versus the prior quarter.
Frequently asked questions
What stocks did Eventide Asset Management own in Q1 2026?
Eventide Asset Management held 213 biotech stocks in their 13F portfolio in Q1 2026. Their top positions include GH, TT, LRCX, MIRM, XMTR. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Eventide Asset Management's portfolio worth in Q1 2026?
Eventide Asset Management's tracked biotech portfolio was worth $4.9B across 213 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Eventide Asset Management buy in Q1 2026?
Eventide Asset Management initiated 30 new positions in Q1 2026, including IRTC, WGSWW, CNTA, WTW, STRO and 25 more. They also increased 122 existing positions.
What did Eventide Asset Management sell in Q1 2026?
Eventide Asset Management fully exited 138 positions in Q1 2026, including VMC, KVUE, KVYO, FICO, AMKR and 133 more. They also trimmed 54 existing positions.
Is Eventide Asset Management a biotech fund?
Values-based investment firm with significant biotech allocation. Kuruvilla—a physician, engineer, and PhD—leads a team that evaluates companies on both financial merit and alignment with ethical principles. Known for holding high-conviction biotech positions alongside broader healthcare and technology investments.
Want AI analysis, insider signals, and catalyst overlays for Eventide Asset Management?
View latest Eventide Asset Managementportfolio →